Progression-free survival with the ICE regimen in refractory RAS/BRAF wild-type and MSS mCRC patients. This is an ASCO Meeting Abstract from the 2026 ASCO Gastrointestinal Cancers Symposium. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results